Catalog No.
DHB95401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
Interferon gamma, IFN-gamma, Immune interferon, IFNG
Concentration
5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01579
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
NI-0501, emapalumab-lzsg, CAS: 1709815-23-5
Clone ID
Emapalumab
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis, PMID: 32374962
Emapalumab for the treatment of hemophagocytic lymphohistiocytosis, PMID: 32648854
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis, PMID: 31537529
Emapalumab: First Global Approval, PMID: 30623346
Emapalumab, PMID: 31643285
Emapalumab, PMID: 30694625
Emapalumab in Primary Hemophagocytic Lymphohistiocytosis, PMID: 32757534
Emapalumab in Primary Hemophagocytic Lymphohistiocytosis. Reply, PMID: 32757535
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking, PMID: 32569708
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL), PMID: 33424859
Antibodies to watch in 2019, PMID: 30516432
Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis, PMID: 33686916
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection, PMID: 32817285
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function, PMID: 31601675
Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections, PMID: 30617216
Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature, PMID: 32793731
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors, PMID: 34169908
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective, PMID: 33754483
Adult haemophagocytic lymphohistiocytosis: a Review, PMID: 31943120
Afebrile S. aureus bacteremia in two patients with hemophagocytic lymphohistiocytosis receiving emapalumab/dexamethasone/etoposide, PMID: 33751768
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation, PMID: 30792213
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders, PMID: 33484058
Antibodies to watch in 2018, PMID: 29300693
Estimating health state utilities in hemophagocytic lymphohistiocytosis, PMID: 33471193
Virus-triggered secondary hemophagocytic lymphohistiocytosis, PMID: 34096649
Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy, PMID: 32447592
Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis, PMID: 31400073
Antibodies to watch in 2017, PMID: 27960628
Case Report: Rapid Recognition and Immune Modulation of Secondary HLH Due to Disseminated HSV Infection, PMID: 34277520
Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation, PMID: 31934312
Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies, PMID: 33888986
Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2, PMID: 33570715
The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders, PMID: 34248986
T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH, PMID: 34173902
X-Linked Lymphoproliferative Disease Mimicking Multisystem Inflammatory Syndrome in Children-A Case Report, PMID: 34414143
Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII, PMID: 34141826
For research use only. Not for human or drug use.
